The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Modafinil (MOD) and its R-enantiomer (R-MOD) are approved medications for narcolepsy and other sleep disorders. They have also been used, off-label, as cognitive enhancers in populations of patients with mental disorders, including substance abusers that demonstrate impaired cognitive function. A debated nonmedical use of MOD in healthy individuals to improve intellectual performance is raising questions about its potential abuse liability in this population. MOD has low micromolar affinity for the dopamine transporter (DAT). Inhibition of dopamine (DA) reuptake via the DAT explains the enhancement of DA levels in several brain areas, an effect shared with psychostimulants like cocaine, methylphenidate, and the amphetamines. However, its neurochemical effects and anatomical pattern of brain area activation differ from typical psychostimulants and are consistent with its beneficial effects on cognitive performance processes such as attention, learning, and memory. At variance with typical psychostimulants, MOD shows very low, if any, abuse liability, in spite of its use as a cognitive enhancer by otherwise healthy individuals. Finally, recent clinical studies have focused on the potential use of MOD as a medication for treatment of drug abuse, but have not shown consistent outcomes. However, positive trends in several result measures suggest that medications that improve cognitive function, like MOD or R-MOD, may be beneficial for the treatment of substance use disorders in certain patient populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aston-Jones, G., & Cohen, J. D. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135709 · Cited by 4,472
Grant, B. F., Chou, S. P., Goldstein, R. B., Huang, B., Stinson, F. S., Saha, T. D., Smith, S. M., Dawson, D. S., Pulay, A. J., Pickering, R. P., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0404 · Cited by 1,618
Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates
Dalley, J. W., Cardinal, R. N., & Robbins, T. W. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.09.006 · Cited by 1,329 · cited 1×
“In fact, the frontal cortex is proposed to mediate executive functions that are essential in enhancing the performance of complex tasks that might comprise of psychological and neurological processes (for a review, see Chudasama and Robbins 2006; Dalley et al. 2004).”
Alheid, G. F., & Heimer, L. (1988) · Neuroscience · doi:10.1016/0306-4522(88)90217-5 · Cited by 1,217
Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling
Lüscher, C., & Malenka, R. C. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.017 · Cited by 1,105 · cited 2×
“NMDA and AMPA receptors are also involved in long-term neuronal adaptations or synaptic plasticity, long-term potentiation (LTP), and longterm depression (Luscher and Malenka 2011; Malenka 1994) that could be related to learning, memory, cognitive processes, and behavioral flexibility (Bowers et al.”
Modafinil: a review of neurochemical actions and effects on cognition
Minzenberg, M. J., & Carter, C. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301534 · Cited by 713 · cited 4×
“2009), direct inhibition of several neurotransmitter transporter systems that lead to increased monoamine transmission have been described (Minzenberg and Carter 2008).”
InfluentialSynaptic plasticity in the hippocampus: LTP and LTD
Malenka, R. C. (1994) · Cell · doi:10.1016/0092-8674(94)90517-7 · Cited by 655 · cited 2×
“…also involved in long-term neuronal adaptations or synaptic plasticity, long-term potentiation (LTP), and longterm depression (Luscher and Malenka 2011; Malenka 1994) that could be related to learning, memory, cognitive processes, and behavioral flexibility (Bowers et al. 2010; Brasil-Neto 2012).”
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568 · cited 1×
“For instance, N-methyl-D-aspartate (NMDA) receptors are believed to play a key role in several disorders characterized by the occurrence of cognitive deficits such as in schizophrenia (Coyle 1996; Tamminga 2006).”
Neuromodulatory transmitter systems in the cortex and their role in cortical plasticity
Gu, Q. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00026-x · Cited by 518
Chudasama, Y., & Robbins, T. W. (2006) · Biological Psychology · doi:10.1016/j.biopsycho.2006.01.005 · Cited by 484 · cited 1×
“In fact, the frontal cortex is proposed to mediate executive functions that are essential in enhancing the performance of complex tasks that might comprise of psychological and neurological processes (for a review, see Chudasama and Robbins 2006; Dalley et al. 2004).”
Deficits in response inhibition associated with chronic methamphetamine abuse
Monterosso, J. R., Aron, A. R., Cordova, X., Xu, J., & London, E. D. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.02.002 · Cited by 425
A Double-Blind, Placebo-Controlled Trial of Modafinil for Cocaine Dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Pettinati, H. M., & O'Brien, C. P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300600 · Cited by 391 · cited 3×
“…good safety and tolerability use of MOD during the 8 weeks of its administration, providing adverse events in <5 % of subjects, it failed to confirm the previously reported significant differences between MOD and placebo over the same measures/effects of cocaine abstinence (Dackis et al. 2012).”
InfluentialFaraone, S. V., & Glatt, S. J. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04902pur · Cited by 387
Chemistry of the mind: Neurochemical modulation of prefrontal cortical function
Robbins, T. W. (2005) · Journal of Comparative Neurology · doi:10.1002/cne.20717 · Cited by 292
Modafinil for the treatment of cocaine dependence
Anderson, A. L., Reid, M. S., Li, S.-H., Holmes, T., Shemanski, L., Slee, A., Smith, E. V., Kahn, R., Chiang, N., Vocci, F., et al. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.015 · Cited by 235 · cited 2×
“Hence, understanding neural correlates to these deficits and implementing cognitive enhancement through therapeutic intervention may, therefore, be beneficial in the treatment strategy for at least some individuals (Anderson et al. 2009; Brady et al. 2011; Heinzerling et al. 2010).”
A double-blind, placebo-controlled trial of modafinil for cocaine dependence
Dackis, C. A., Kampman, K. M., Lynch, K. G., Plebani, J. G., Pettinati, H. M., Sparkman, T., & O'Brien, C. P. (2012) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2011.12.014 · Cited by 187
Mechanisms of modafinil: A review of current research
Gerrard, P., & Malcolm, R. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.a911 · Cited by 160 · cited 3×
“As observed by Gerrard and Malcolm (2007), an interesting feature about MOD's effects on glutamate transmission is found in the inconsistent pattern of activation of this brain neurotransmitter .”
InfluentialA double‐blind, placebo‐controlled trial of modafinil (200 mg/day) for methamphetamine dependence
Shearer, J., Darke, S., Rodgers, C., Slade, T., Van Beek, I., Lewis, J., Brady, D., McKetin, R., Mattick, R. P., & Wodak, A. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02437.x · Cited by 159 · cited 3×
“…subjects, none of them found statistically significant improvements in urine detection of metabolites, abstinence, depressive symptoms, or craving (Anderson et al. 2012; De La Garza et al. 2010; Heinzerling et al. 2010; Hester et al. 2010; Lee et al. 2013; McGaugh et al. 2009; Shearer et al. 2009).”
Heinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105 · cited 5×
“…subjects, none of them found statistically significant improvements in urine detection of metabolites, abstinence, depressive symptoms, or craving (Anderson et al. 2012; De La Garza et al. 2010; Heinzerling et al. 2010; Hester et al. 2010; Lee et al. 2013; McGaugh et al. 2009; Shearer et al. 2009).”
InfluentialAssociation between tobacco smoking and cognitive functioning in young adults
Chamberlain, S. R., Odlaug, B. L., Schreiber, L. R. N., & Grant, J. E. (2012) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2012.00290.x · Cited by 100
Porter, J. N., Olsen, A. S., Gurnsey, K., Dugan, B. P., Jedema, H. P., & Bradberry, C. W. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5426-10.2011 · Cited by 97
Modulatory Effects of Modafinil on Neural Circuits Regulating Emotion and Cognition
Rasetti, R., Mattay, V. S., Stankevich, B., Skjei, K., Blasi, G., Sambataro, F., Arrillaga-Romany, I. C., Goldberg, T. E., Callicott, J. H., Apud, J. A., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.83 · Cited by 83
Behavioral and subjective effects of D-amphetamine and modafinil in healthy adults.
Makris, A. P., Rush, C. R., Frederich, R. C., Taylor, A. C., & Kelly, T. H. (2007) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.15.2.123 · Cited by 68
Kalechstein, A. D., De La Garza, II, & Newton, T. F. (2010) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2010.00052.x · Cited by 67
Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse
Sweeney, C. T., Sembower, M. A., Ertischek, M. D., Shiffman, S., & Schnoll, S. H. (2013) · Journal of Addictive Diseases · doi:10.1080/10550887.2012.759858 · Cited by 65 · cited 1×
“However, misuse of prescription ADHD medications in the USA is very common, especially among young adults, 18 to 25 years of age (see, for example, Sweeney et al. 2013).”
Verdejo‐Garcia, A., Contreras‐Rodríguez, O., Fonseca, F., Cuenca, A., Soriano‐Mas, C., Rodriguez, J., Pardo‐Lozano, R., Blanco‐Hinojo, L., de Sola Llopis, S., Farré, M., et al. (2014) · Addiction Biology · doi:10.1111/j.1369-1600.2012.00472.x · Cited by 53
Hester, R., Lee, N., Pennay, A., Nielsen, S., & Ferris, J. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0021791 · Cited by 42 · cited 3×
“…subjects, none of them found statistically significant improvements in urine detection of metabolites, abstinence, depressive symptoms, or craving (Anderson et al. 2012; De La Garza et al. 2010; Heinzerling et al. 2010; Hester et al. 2010; Lee et al. 2013; McGaugh et al. 2009; Shearer et al. 2009).”
Cited by
Deficits in behavioural inhibition in substance abuse and addiction: a meta-analysis.
Smith, J. L., Mattick, R. P., Jamadar, S. D., & Iredale, J. M. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.009 · Cited by 546
Angarita, G. A., Emadi, N., Hodges, S., & Morgan, P. T. (2016) · Addiction Science & Clinical Practice · doi:10.1186/s13722-016-0056-7 · Cited by 358
An Overview of the Clinical Uses, Pharmacology, and Safety of Modafinil
Murillo-Rodríguez, E., Barciela Veras, A., Barbosa Rocha, N., Budde, H., & Machado, S. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00374 · Cited by 91
Serotonin, neural markers, and memory
Meneses, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00143 · Cited by 90
“Moreover, diverse evidence indicates that memory formation, forgetting, amnesia, and/or anti-amnesic effects can also be modulated by changes in the expression of neurotransmitter transporters (e.g., Schmitt and Hiemke, 2002; Chen et al., 2011; Reichel et al., 2012; Yang et al., 2013).”
BackgroundBisagno, V., González, B., & Urbano, F. J. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.013 · Cited by 59
Metadata
- Authors
- Mereu, M., Bonci, A., Newman, A. H., & Tanda, G.
- Venue
- Psychopharmacology
- Published
- 2013-08-10
- Volume
- 229
- Issue
- 3
- Pages
- 415-434
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2028455835
- Cited by
- 148
- References
- 27
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.